Arylesterase activity and antioxidant status depend on PON1-Q192R and PON1-L55M polymorphisms in subjects with increased risk of cardiovascular disease consuming walnut-enriched meat

Journal of Nutrition

Volumn 137, Issue 7, 2007, Pages 1783-1788

  Nus, Meritxell ^a   Frances, Francesc ^b   Librelotto, Josana ^a   Canales, Amaia ^a   Corella, Dolores ^b   Sánchez Montero, José M ^a   Sánchez Muniz, Francisco J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CARBOHYDRATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY ACID;

ADULT; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIETARY INTAKE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; FOOD INTAKE; HUMAN; LIPID PEROXIDATION; MALE; MEAT; WALNUT;

JUGLANS;

EID: 34447116322     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/137.7.1783     Document Type: Article

References (32)

1. Parthasarathy S, Barnett J, Fong LG. High-density lipoproteins inhibit the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-83.
2. Canales A, Sánchez-Muniz FJ. La paraoxonasa, ¿algo más que un enzima? Med Clin (Barc). 2003;121:537-48.
3. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih D, Fonarow GC. Paraoxonase and coronary heart disease. Curr Opin Lipidol. 1998;9:319-24.
4. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL. La Du BN. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions, a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-90.
5. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
6. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62-6.
7. Davies H, Richter RJ, Kiefer M, Broomfield C, Sowalla J, Furlong CE. The human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996;14:334-6.
8. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997;122:265-8.
9. La Du BN, Piko JI, Eckerson HW, Vincent-Viry M, Siest G. An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism. Ann Biol Clin (Paris). 1986;44:369-72.
10. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid arteriosclerotic lesions. Circulation. 2000;101:2510-7.
11. Tomás M, Sentí M, Elosua R, Vila J, Sala J, Masià R, Marrugat J. Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high density lipoprotein cholesterol and paraoxonase activity. Eur J Pharmacol. 2001;432:121-8.
12. Bub A, Barth S, Watzi B, Briviba K, Herbert BM, Luhrmann PM, Neuhauser-Berthold M, Rechkemmer G. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in R-allele carrier bt not in QQ-homozygous elderly subjects on a tomato-rich diet. Eur J Nutr. 2002;41:237-43.
13. Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G, Aro A, Kesaniemi YA. Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr. 2002;132:3012-7.
14. Bub A, Barth SW, Watzl B, Briviba K, Rechkemmer G. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet supplemented with tomato juice. Br J Nutr. 2005;93:291-7.
15. Sabaté J, Fraser GE, Burke K, Knutsen S, Bennett H, Lindsted KD. Effects of walnuts on serum lipids levels and blood pressure in normal men. N Engl J Med. 1993;328:603-7.
16. Almario RU, Vonghavaravat V, Wong R, Kasim-Karakas SE. Effects of walnuts consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia. Am J Clin Nutr. 2001;74:72-9.
17. Zambon D, Sabate J, Muñoz S, Campero B, Casals E, Merlos M, Laguna J, Ros E. Substituting walnuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women: a randomized crossover trial. Ann Intern Med. 2000;132:538-49.
18. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb. 1992; 12:911-19.
19. Serrano A, Cofrades S, Ruiz-Capillas C, Olmedilla-Alonso B, Herrero-Barbudo C, Jiménez-Colmenero F. Nutritional profile of restructured beef steak with added walnuts. Meat Sci. 2005;70:647-54.
20. Olmedilla-Alonso B, Granado-Lorencio F, Herrero-Barbudo C, Blanco-Navarro I, Blázquez-García S, Pérez-Sacristan B. Consumption of restructured meat products with added walnuts has a cholesterol-lowering effect in subjects at high cardiovascular risk: a randomised, crossover, placebo-controlled study. J Am Coll Nutr. 2007; in press.
21. Moreiras O, Carbajal A, Cabrera L, eds. Tablas de composición de Alimentos. Madrid: Editorial Pirámide; 2001.
22. Motti C, Dessi M, Gnasso A, Irace C, Indigeno P, Angelucci CB, Bernardini S, Fucci G, Federici G, Cortese C. A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphisms. Atherosclerosis. 2001;158:35-40.
23. Nus M, Sánchez-Muniz FJ, Sánchez-Montero JM. A new method for the determination of arylesterase activity in human serum using simulated body fluid. Atherosclerosis. 2006;188:155-9.
24. Friedewald WT, Levy RI, Fredickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
25. Tushuizen ME, Nieuwland R, Scheffer PG, Sturk A, Heine RJ, Diamant M. Two consecutive high fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. J Thromb Haemost. 2006;4:1003-10.
26. Bardsley WG. SIMFIT 5.4, a computer package for simulation, curve fitting statistical analysis in the life sciences. Manchester (UK): Manchester University; 2004.
27. Tomas M, Senti M, García-Faria F, Vila J, Torrents A, Covas M, Marrugat J. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2000;20:2113-9.
28. Sentí M, Aubó C, Elosua R, Tomás M, Marrugat J. Effect of physical activity on lipid levels in a population based sample of men with and without the arg variant of the human paraoxonase gene. Genet Epidemiol. 2000;18:276-86.
29. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35: 214-27.
30. Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA, Gortner DA, Boyko E, Schellenberg GD, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res. 2005;46: 1888-95.
31. Turay J, Grniakova V, Valka J. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate. Drugs Exp Clin Res. 2000;26: 83-8.
32. Nus M, Ruperto M, Sánchez-Muniz FJ. Frutos secos y riesgo cardio y cerebrovascular. Una perspectiva española. [Nuts and cardio and cerebrovascular risk. A Spanish perspective]. Arch Latinoam Nutr. 2004;54: 137-48.